Constructing a Ready-to-Use mRNA Vaccine Delivery System for the Prevention of Influenza A virus, Utilizing FDA-Approved Raw Materials

文献类型： 外文期刊

第一作者： Zhang, Yuyan

作者： Zhang, Yuyan;Hu, Yingying;Chen, Jie;Tang, Zhaohui;Tian, Huayu;Chen, Xuesi;Zhang, Yuyan;Hu, Yingying;Chen, Jie;Tang, Zhaohui;Tian, Huayu;Chen, Xuesi;Zhuang, Xinyu;Tian, Mingyao;Jin, Ningyi;Hao, Kai;Tian, Huayu;Tian, Huayu

作者机构：

期刊名称：BIOMACROMOLECULES （ 影响因子：6.2； 五年影响因子：6.5 ）

ISSN： 1525-7797

年卷期： 2024 年

页码：

收录情况： SCI

摘要： Messenger ribonucleic acid (mRNA) vaccines, serving as a rapid and easily scalable emergency preventive measure, have played a pivotal role in preventing infectious diseases. The effectiveness of mRNA vaccines heavily relies on the delivery carrier, but the current market options are predominantly lipid nanoparticles. Their intricate preparation process and high transportation costs pose challenges for widespread use in remote areas. In this study, we harnessed FDA-approved polymer PLGA and lipid components widely employed in clinical experiments to craft a ready-to-use mRNA vaccine delivery system known as lipid-polymer hybrid nanoparticles (LPP). Following formulation optimization, the PDCD nanoparticles emerged as the most effective, showcasing exceptional mRNA delivery capabilities both in vitro and in vivo. Loading PDCD nanoparticles with mRNA encoding the H1N1 influenza virus HA antigen-fused M2e peptide enabled the successful induction of M2e-specific antibodies and T cell immune responses in immunized mice. After three rounds of vaccine immunization, the mice demonstrated weight recovery to normal levels and maintained a survival rate exceeding 80% following an encounter with the H1N1 influenza virus. The innovative mRNA delivery system that we designed demonstrates outstanding effectiveness in preventing infectious diseases, with the potential to play an even more significant role in future clinical applications.

分类号：

  • 相关文献
作者其他论文 更多>>

微信小程序